Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD84 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD84 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD84 Products |
| Gene Delivery | CD84 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD84 Products |
| Benchmark Ab | Anti-CD84 (Sequence of clinical/preclinical clones) Recombinant positive control. |
View CD84 Products |
| Validator | CD84 siRNA Set For knockdown verification. |
View CD84 Products |
| Related Target A | SLAMF6 Close homolog in the SLAM family; essential for off-target selectivity screening. |
View SLAMF6 Products |
| Related Target B | SLAMF7 Validated hematological target (Elotuzumab pathway); useful for comparative efficacy panels. |
View SLAMF7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homophilic Interaction Mimicry | HEK293 Expressed (Native Glycosylation) ECD-Fc fusion proteins preserving natural homophilic binding conformation. |
| SLAM Family Off-Target Screening | Homolog panel proteins (SLAMF1, SLAMF3, SLAMF6, SLAMF7) strictly sequence verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD84 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD84 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific constructs. As first-generation therapies reach the clinic, the next wave of R&0 is targeting microenvironmental survival signaling in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) to overcome drug resistance to standard B-cell receptor inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic Consortiums, Biotech Startups | Chronic Lymphocytic Leukemia (CLL) | Internalization Assay (Need high-purity ECD-Fc to validate antibody-induced receptor endocytosis) |
| Blocking mAb | Preclinical Stage Biopharma | Autoimmune Diseases, Lymphoma | Homophilic Blocking Assay (Requires high-affinity, native glycosylated CD84 proteins to evaluate disruption of self-binding) |
| Bispecific / Cell Engager | Immuno-oncology Innovators | Multiple Myeloma (MM) | Dual-Target Binding Verification (Requires robust stable cell lines generated via Lentivirus ORF) |